US · ACTU
Actuate Therapeutics Inc
- Sector
- Healthcare · Biotechnology
- Headquarters
- Fort Worth, TX 76107
- Website
- actuatetherapeutics.com
Price · as of 2024-12-31
$3.00
Market cap 86.93M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $6.95 |
AI valuation
Our deep-learning model estimates Actuate Therapeutics Inc's (ACTU) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $3.00
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ACTU | Actuate Therapeutics Inc | $3.00 | 86.93M | — | — | — | — | -4.97 | 1301.78 | — | -5.05 | -5.09 | 1301.78 | 0.00% | — | — | 54.83% | 45.28% | -443.16% | 0.00 | 1344.27 | 1.05 | 0.98 | 0.34 | 9758.00% | — | 101.00% | -16.10% | -2.48 | 39.31% | 0.00% | 0.00% | 4.19% | -5.05 | -5.81 | — | -19.92 |
| ALEC | Alector, Inc. | $2.43 | 265.24M | +1,084% | -64% | — | +3,751% | -1.59 | 7.43 | 10.82 | -0.06 | -12.24 | 7.43 | 54.09% | -692.83% | -679.16% | -181.56% | 67.31% | -37.54% | 1.18 | — | 3.83 | 3.68 | 0.22 | 1301.00% | -7907.00% | -2037.00% | -80.87% | -2.65 | 84.98% | 0.00% | 0.00% | 17.16% | -0.05 | -0.04 | 0.37 | -4.88 |
| APLT | Applied Therapeutics, Inc… | $0.10 | 14.86M | +30,191% | +123% | — | +60,988% | -0.76 | 1.40 | 175.54 | -0.03 | — | 1.40 | 100.00% | -22922.86% | -23214.07% | -529.97% | 242.94% | -149.27% | 0.05 | — | 3.06 | 2.91 | 0.74 | -4648.00% | -9545.00% | 5280.00% | -105.55% | -3.09 | 196.37% | 0.00% | 0.00% | 34.41% | -0.03 | -0.04 | 7.18 | -10.84 |
| ELTX | Elicio Therapeutics, Inc. | $12.99 | 224.19M | — | — | — | — | -1.86 | -8.51 | — | -2.08 | — | -8.51 | 0.00% | — | — | -170157.38% | -3590.26% | -187.61% | -2.30 | -98.87 | 1.80 | 1.53 | -0.17 | -3894.00% | — | 1342.00% | -38.59% | -3.22 | -2965.28% | 0.00% | 0.00% | 0.00% | -2.33 | -2.82 | — | -13.06 |
| MCRB | Seres Therapeutics, Inc. | $8.74 | 79.07M | — | — | — | — | 875.27 | 8.64 | — | -1.50 | 14208.58 | 8.64 | 0.00% | — | — | -0.88% | -241.20% | 0.05% | 6.65 | — | 0.94 | 0.86 | -0.51 | 616.00% | — | 1888.00% | -125.16% | -3.61 | -296.22% | 0.00% | 0.00% | 8.38% | -1.48 | -1.21 | — | -12.11 |
| MOLN | Molecular Partners AG | $5.02 | 187.84M | +527% | -29% | — | +690% | -2.52 | 0.96 | 27.41 | 0.21 | — | 0.96 | -855.81% | -1231.73% | -1087.38% | -33.98% | 1006.36% | -30.29% | 0.02 | -2448.68 | 14.31 | 13.88 | 1.19 | -1587.00% | -2938.00% | 26.00% | -44.02% | -5.49 | 985.88% | 0.00% | 0.00% | 0.00% | 0.18 | 0.18 | -2.17 | 2.51 |
| NKTX | Nkarta, Inc. | $2.70 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
| PEPG | PepGen Inc. | $6.22 | 427.61M | — | — | — | — | -0.81 | 0.61 | — | 0.32 | — | 0.61 | 0.00% | — | — | -79.26% | -551.43% | -61.23% | 0.16 | — | 7.41 | 7.20 | 0.35 | -1364.00% | — | 1575.00% | -113.83% | -4.93 | -470.74% | 0.00% | 0.00% | 0.00% | 0.29 | 0.35 | — | -2.45 |
| SPRO | Spero Therapeutics, Inc. | $2.17 | 122.26M | +1,351% | -86% | — | +2,434% | -0.61 | 0.91 | 0.88 | 0.09 | — | 0.91 | -101.67% | -152.91% | -142.91% | -89.62% | -436.22% | -46.81% | 0.09 | — | 2.19 | 2.15 | 0.67 | -39535.00% | -5377.00% | -2895.00% | -55.69% | -0.48 | -139.40% | 0.00% | 0.00% | 0.00% | 0.09 | 0.28 | -0.14 | -6.55 |
| VOR | Vor Biopharma Inc. | $15.44 | 105.82M | — | — | — | — | -0.59 | 0.71 | — | -0.07 | — | 0.71 | 0.00% | — | — | -94.52% | -282.56% | -66.29% | 0.33 | — | 5.19 | 4.94 | 0.43 | -286.00% | — | -145.00% | -145.39% | -5.35 | -232.90% | 0.00% | 0.00% | 79.21% | -0.07 | -0.09 | — | -5.73 |
| VTGN | VistaGen Therapeutics, In… | $0.59 | 19.2M | +3,740% | +110% | — | +12,444% | -1.41 | 1.03 | 149.14 | 0.12 | -14.28 | 1.03 | 100.00% | -11517.08% | -10579.84% | -55.68% | 986.92% | -49.44% | 0.02 | — | 6.51 | 6.38 | 1.19 | 987.00% | -5432.00% | 6344.00% | -58.34% | -3.34 | 745.62% | 0.00% | 0.00% | 0.00% | 0.12 | 0.15 | -13.36 | -4.85 |
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
- CEO
- Daniel Schmitt
- Employees
- 10
- Beta
- 0.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $3.00) − 1 = — (DCF, example).